

HE Dr. Ferozuddin Feroz,  
The Minister of Public Health  
Ministry of Public Health  
Great Masoud Road  
Kabul  
The Islamic Republic of  
Afghanistan

26 March 2018

***Decision Letter: Request for Gavi support for Measles Follow-up campaign***

Your Excellency,

I am writing in relation to Afghanistan's application for New Vaccines Support (NVS) for Measles Follow-up campaign, which was submitted to the Gavi Secretariat in September 2017.

Following the recommendations made by the Independent Review Committee (IRC), I am pleased to inform you that Gavi has **approved** Afghanistan's application for Measles Follow-up campaign, subject to several conditions and requirements as specified in the Appendices to this letter.

Please do not hesitate to contact my colleague Mr Ricard Lacort, Senior Country Manager for Afghanistan, at [rlacort@gavi.org](mailto:rlacort@gavi.org) if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman  
Managing Director, Country Programmes

Appendix A: Financial and Programmatic information – Measles Follow-up campaign  
Appendix B: Financial and Programmatic information – Injection Safety Devices

cc: The Minister of Finance  
The EPI Manager  
WHO Country Representative  
UNICEF Country Representative  
Regional Working Group  
WHO HQ  
UNICEF Programme Division  
UNICEF Supply Division

**Decision Letter**  
**Afghanistan - Support for Measles Vaccine Follow-up Campaign**

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Afghanistan		
<b>2. Grant number:</b> 18-AFG-36a-X / 18-AFG-37a-Y		
<b>3. Date of Decision Letter:</b> 26/03/2018		
<b>4. Date of the Partnership Framework Agreement:</b> 30/04/2013		
<b>5. Programme title:</b> New Vaccine Support (NVS), Measles Follow-up campaign		
<b>6. Vaccine type:</b> Measles		
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 doses per vial, LYOPHILISED		
<b>8. Programme duration<sup>1</sup>:</b> 2018		
<b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement)		
	<b>2018</b>	<b>Total<sup>2</sup></b>
<b>Programme Budget (US\$)</b>	4,307,000	4,307,000
<b>10. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>		
Type of supplies to be purchased with Gavi funds in each year (Campaign)	2018	
Number of vaccines doses	14,563,800	
<b>Annual Amounts (US\$)</b>	<b>4,307,000</b>	
<b>11. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>12. Self-procurement:</b> Not applicable		
<b>13. Co-financing obligations for routine:</b> Not applicable		
<b>14. Co-financing obligations for campaign:</b> Reference code: 18-AFG-36a-X-C The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.		
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>2018</b>	
Number of vaccine doses	297,300	
Value of vaccine doses (US\$)	80,250	
<b>Total co-financing payments (US\$) (including freight)</b>	<b>88,000</b>	
<b>15. Vaccine introduction grant (in US\$):</b> Not applicable.		
<b>16. Operational support for campaigns:</b> The support for operational costs for campaign will be disbursed in cash through WHO and UNICEF. The Country will need to contact the local WHO and UNICEF office to arrange the utilisation of GAVI funds to support the operational costs of the campaign. Payable up to six months before campaign.		
	<b>2018</b>	
<b>Grant amount (US\$)</b>	<b>8,702,377</b>	

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**17. Additional reporting requirements:** Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign	Within 3 months of end of campaign
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign	As soon as available

**18. Financial clarifications:** Not applicable.

**19. Other conditions:** Not applicable.

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
26 March 2018

**Decision Letter  
Afghanistan - Support for Injection Safety Devices**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Afghanistan				
<b>2. Grant number:</b> 17-AFG-32a-X; 18-AFG-32a-X; 19-AFG-32a-X;				
<b>3. Date of Decision Letter:</b> 26/03/2018				
<b>4. Date of the Partnership Framework Agreement:</b> 30/04/2013				
<b>5. Programme title:</b> Injection safety devices <sup>4</sup>				
<b>6. Programme duration<sup>5</sup>:</b> 2017-2019				
<b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)				
	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>Total<sup>6</sup></b>
Programme Budget (US\$)	617,500	1,042,000	310,500	1,970,000
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>7</sup>				
<b>TOTAL</b> injection safety devices to be purchased with Gavi funds in each year	2017	2018		
Number of AD syringes			21,116,200	
Number of re-constitution syringes			1,634,800	
Number of safety boxes			250,300	
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>617,500</b>	<b>1,042,000</b>		
<b>Injection safety devices to be purchased with Gavi funds in each year, by type of support</b>				
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine</b>				<b>2018</b>
Number of AD syringes				1,481,800
Number of safety boxes				16,300
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>				<b>67,500</b>
<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 4 doses per vial, LIQUID, Routine</b>				<b>2018</b>
Number of AD syringes				3,983,600
Number of safety boxes				43,825
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>				<b>180,500</b>

<sup>4</sup> This does not include vaccines.

<sup>5</sup> This is the entire duration of the Programme.

<sup>6</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>7</sup> This is the amount that Gavi has approved.

<b>New Vaccine Support (NVS), DTP-HepB-Hib, 10 doses per vial, LIQUID, Routine</b>	<b>2018</b>
Number of AD syringes	923,600
Number of safety boxes	10,175
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>42,000</b>
<b>New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, Follow-up campaign</b>	<b>2018</b>
Number of AD syringes	14,727,200
Number of re-constitution syringes	1,634,800
Number of safety boxes	180,000
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>752,000</b>
<b>9. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
<b>10. Self-procurement:</b> Not applicable.	
<b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
26 March 2018